Share this article
KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ Researchers at Kanazawa University report in
Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however.
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly used for treating patients with NSCLC. It addresses a gene rearrangement known as ALK that occurs in 3 to 5% of NSCLC patients (alectinib belongs to a class of drugs called ALK tyrosine kinase inhibitors). It has been unclear, however, whether there is a correlation between the use of alectinib and the poore
December 11th, 2020 By David Knox 2 commentsFiled under: Programming,
2017 food special
Expect the word “journey.”
Maggie has been intrigued by Japanese food for 20 years and has decided its finally time to put her fears aside and travel to Japan to master its flavours.
Maggie Beer’s cooking has always been inspired by the use of the freshest local produce in season and she describes herself as a Mediterranean cook who lives in the Barossa, SA. But she has a food secret; for 20 years she has been intrigued by Japanese food. She sets off to Japan, fired by her love of learning and a challenge to produce an exciting Japanese inspired feast for her Barossa friends.